Aditxt stock.

Nov 24, 2023 · Grading Aditxt Inc Stock. Before you choose to buy, sell or hold Aditxt Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. Get the latest Aditxt, Inc. (ADTX) stock news and headlines to help you in your trading and investing decisions.Dec 1, 2023 · Stock analysis for Aditxt Inc (ADTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Aditxt stock price has plummeted: avoid at all cost. Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.

Aditxt, Inc. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: ADTX | Nasdaq

Aditxt's CEO is Amro Albanna, appointed in Jan 2017, has a tenure of 6.83 years. total yearly compensation is $500.00K, comprised of 100% salary and 0% bonuses, including company stock and options.

Aditxt Inc ( ADTX) is up 11.47% today. ADTX has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on ADTX! ADTX stock closed at $3.40 and is up $0.39 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours.Nov 30, 2023 · Aditxt (NASDAQ:ADTX) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange ... Webull offers ADTX stock news, real time Aditxt Inc news help you invest smart.Aditxt, Inc. (NASDAQ: ADTX) shares are blasting higher Thursday despite a lack of company-specific news. Despite today's gains, the stock remains down by more than 20% over the last month.

In conclusion, Aditxt Inc (ADTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

30 Jun 2020 ... Each unit will immediately separate into one share of common stock, one Series A warrant, and one Series B warrant. The Series A warrants ...

Aditxt stock is rising higher on Thursday as investors react to heavy trading of ADTX shares despite a lack of news today.More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move ...Nov 30, 2023 · Aditxt (NASDAQ: ADTX) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange ... Aditxt, Inc. to Present at 8th Annual Dawson James Conference. Track Aditxt Inc (ADTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.All values updated annually at fiscal year end. Earnings Per Share -595.50. Sales 20.14. Tangible Book Value 47.38. Operating Profit -537.79. Working Capital 10.22. Long Term Liabilities 17.51 ...The latest Aditxt stock prices, stock quotes, news, and ADTX history to help you invest and trade smarter.Which Aditxt insiders have been selling company stock? The following insider sold ADTX shares in the last 24 months: Paribas Securities Corp Bnp ($691,184.00). How much insider selling is happening at Aditxt?

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common ...Aditxt (NASDAQ:ADTX) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange ...Aditxt, inc. Shares are up 28% thursday. Aditxt is a life sciences company that develops products to induce tolerance to transplanted organs. The stock is down more than 20% over the last month. Adtx shares hit a premarket high of $8.27. Immunogen imgn, aditxt, sutro biopharma among healthcare movers.Aditxt’s monitoring service is based on a comprehensive evaluation of the immune response to the virus or vaccine. AditxtScore provides meaningful information to help understand one’s personal immune response to COVID and not just that of the population collectively. Learn more about what your results mean in this video. From the White ...Sep 28, 2023 · Aditxt Inc (ADTX) stock is trading at $14.75 as of 10:47 AM on Thursday, Sep 28, a rise of $1.71, or 13.15% from the previous closing price of $13.04. The stock has traded between $13.33 and $24.00 so far today. Volume today is low. So far 308,003 shares have traded compared to average volume of 419,078 shares. Aditxt, Inc. has entered into revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company's $14.5 million loan, plus interest to Cellvera Global Holdings LLC (“Cellvera”), formerly AiPharma Global Holdings …

4 days ago ... Cision PR Newswire · Thinking about buying stock in Aditxt Inc, Ampio Pharmaceuticals, TOP SHIPS, Mullen Automotive, or Oatly Group ? · Get News ...Aditxt (NASDAQ:ADTX) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange ...

08/31/2023 - 07:00 PM . RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an …Aditxt’s monitoring service is based on a comprehensive evaluation of the immune response to the virus or vaccine. AditxtScore provides meaningful information to help understand one’s personal immune response to COVID and not just that of the population collectively. Learn more about what your results mean in this video. From the White ...Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common …Aditxt (ADTX) disclosed in a filing on Friday a prospectus for a common stock offering of up to 2.06M shares by selling stockholders.ADTX shares down 2% aftermarket.FilingAditxt, Inc. has entered into revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company's $14.5 million loan, plus interest to Cellvera Global Holdings LLC (“Cellvera”), formerly AiPharma Global Holdings …Nov 30, 2023 · Aditxt, Inc. (NASDAQ: ADTX) shares are blasting higher Thursday despite a lack of company-specific news. Despite today's gains, the stock remains down by more than 20% over the last month. Aditxt Inc. stock performance at a glance Check Aditxt Inc. ’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADTX Stock PerformanceAditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives. At …

Aditxt, Inc. (ADTX) latest earnings report: revenue, EPS, surprise, history, news and analysis.

Additional information concerning the reverse stock split can be found in Aditxt’s definitive proxy statement filed with the Securities and Exchange Commission on August 1, 2022, as amended ...

Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 15th, …The purpose of this Amendment No. 1 on Form 10-K/A (the “Amendment”) is to amend and restate Part III, Items 10 through 14 of the previously filed Annual Report on Form 10-K of Aditxt, Inc. (the “Company”) for the year ended December 31, 2022, filed with the Securities and Exchange Commission on April 17, 2023 (the “Original Form 10-K”), to include information previously omitted in ...Get the latest Aditxt Inc (ADTX) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the second quarter of 2023. RICHMOND, Va., February 14, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and ...Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules. RICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today …Aditxt, Inc., , an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of its previously announced... | June 17, 2023Additional information concerning the reverse stock split can be found in Aditxt’s definitive proxy statement filed with the Securities and Exchange Commission on July 20, 2023, as amended ...Aditxt's stock closed Friday at 87.49 cents per share. Pfizer's stock closed at $41.19. Amro Albanna, the co-founder, chairman and CEO of Richmond, Virginia-based Aditxt, contended that picking ...Second, Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 million shares of common stock ...Aditxt, Inc.® (NASDAQ: ADTX) is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, with operations in Silicon Valley, California, and New York, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” …Find out all the key statistics for Aditxt, Inc. (ADTX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price History. Beta ...Dec 1, 2023 · According to 1 stock analyst, the 12-month stock price forecast for Aditxt stock is $61, which predicts an increase of 1,694.12%. On average, analysts rate Aditxt stock as a strong buy.

Aditxt, Inc. (ADTX) is a global innovation activation company that discovers, develops, and deploys technologies that monitor and modulate the immune system. The stock price, news, quote, history, and research reports of ADTX are available on Yahoo Finance. See the latest updates on its performance outlook, earnings date, dividend yield, and more. Aditxt, Inc., (NASDAQ: ADTX) (' Aditxt ' or the 'Company'), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ('Pearsanta'), to accelerate the growth of Aditxt's …Nov 27, 2023 · Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic ... Aditxt, Inc. ADTX shares rose 126.1% to $7.80 in pre-market trading. ... jumped 93% on Wednesday after the company effected a 1-for-10 reverse stock split for its Class A and Class B common stock.Instagram:https://instagram. foreign exchange trading trainingcost of paganiups salesmicrosoft ex dividend date Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Aditxt Inc (NASDAQ: ADTX) has experienced a decline in its stock price by -14.36 compared to its previous closing price of 3.97. However, the company has seen a fall of -6.34% in its stock price over the last five trading days. InvestorPlace reported 2023-11-30 that Aditxt (NASDAQ: ADTX ) stock is rocketing higher on Thursday despite […] spy vs qqqmost successful swing traders ADTX Stock and the Reverse Split. Yesterday afternoon, Aditxt announced that it would carry out “a 1-for-50 reverse split of its common stock” to go into effect yesterday at 4:01 pm Eastern ...Nov 30, 2023 · Aditxt (NASDAQ:ADTX) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. No new press releases or filings with the Securities and Exchange Commission (SEC ... new casamigos tequila Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split SA News Tue, Sep. 13, 2022 Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate